Skip to main content

Table 1 Main characteristics of the entire study population

From: Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study

Characteristics

Patients with IIMs and cancer

Patients with CAMa

Patients with IIMs without cancer

Number of patients

72

60

545

Myositis subtype, n (%)

   

 PM

6 (8.3)

3 (5.0)

92 (16.9)

 DM

63 (87.5)

56 (93.3)

418 (76.7)

 IMNM

3 (4.2)

1 (1.7)

35 (6.4)

 Male, n (%)

26 (36.1)

24 (40%)

168 (30.8)

 Age at myositis onset, mean ± SD years

57.7 ± 14.2

58.0 ± 13.1

47.0 ± 14.1

 Age at cancer diagnosis, mean ± SD years

57.5 ± 13.6

58.4 ± 12.9

NA

 Time from first symptoms to myositis diagnosis, mean ± SD months (n)

12.3 ± 35.6 (72)

7.9 ± 21.9 (60)

22.1 ± 35.1 (512)

 Cancer prior to the onset of myositis, mean ± SD, months (n)

56.1 ± 91.3 (19)

11.8 ± 13.4 (13)

NA

 Cancer after the onset of myositis, mean ± SD, months (n)

22.8 ± 42.8 (53)

11.7 ± 12.5 (47)

NA

 Follow up, median, IQR, months (n)

20.0, 9.0–45.0 (67)

19.0, 9.0–41.8 (55)

34.0,15.0–63.0 (507)

  1. Abbreviations: n number, CAM cancer-associated myositis, IIMs idiopathic inflammatory myopathies, PM polymyositis, DM dermatomyositis, IMNM immune-mediated necrotizing myopathy, SD standard deviation, IQR interquartile range, NA not applicable
  2. aCAM was defined as cancer occurring within 3 years of the disease onset (before or after), in addition, those who had paraneoplastic features but the interval between the onset of myositis and cancer diagnosis was > 3 years were also considered to have CAM